OPTIMIZATION of NONCODING REGIONS IMPROVES mRNA SARS-CoV-2 VACCINE in NHPs
Topics in Antiviral Medicine
; 30(1 SUPPL):95, 2022.
Article
in English
| EMBASE | ID: covidwho-1880255
ABSTRACT
Background:
The CVnCoV (CureVac) mRNA vaccine for SARS-CoV-2 has recently been evaluated in a Phase IIb/III efficacy trial in humans. CV2CoV is a second-generation mRNA vaccine with optimized non-coding regions and enhanced antigen expression.Methods:
Here we report a head-to-head study of the immunogenicity and protective efficacy of CVnCoV and CV2CoV in nonhuman primates. We immunized 18 cynomolgus macaques with two doses of 12 ug of lipid nanoparticle formulated CVnCoV, CV2CoV, or sham (N=6/group).Results:
CV2CoV induced substantially higher binding and neutralizing antibodies, memory B cell responses, and T cell responses as compared with CVnCoV. CV2CoV also induced more potent neutralizing antibody responses against SARS-CoV-2 variants, including B.1.351 (beta), B.1.617.2 (delta), and C.37 (lambda). While CVnCoV provided partial protection against SARS-CoV-2 challenge, CV2CoV afforded robust protection with markedly lower viral loads in the upper and lower respiratory tract. Antibody responses correlated with protective efficacy.Conclusion:
These data demonstrate that optimization of non-coding regions can greatly improve the immunogenicity and protective efficacy of an mRNA SARS-CoV-2 vaccine in nonhuman primates.
lipid nanoparticle; neutralizing antibody; zorecimeran; animal experiment; antibody response; conference abstract; controlled study; drug efficacy; human; immunogenicity; lower respiratory tract; Macaca fascicularis; memory B lymphocyte; nonhuman; SARS-CoV-2 Beta; SARS-CoV-2 Delta; Severe acute respiratory syndrome coronavirus 2; T lymphocyte; virus load
Search on Google
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Vaccines
Language:
English
Journal:
Topics in Antiviral Medicine
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS